Ongoing Education and Support for Jakafi® (ruxolitinib)

Learn about ongoing education and personalized support about your condition and Jakafi from an IncyteCARES oncology certified nurse. Hear about how IncyteCARES nurses help patients navigate through their journey with Jakafi. View the video to learn more.

IncyteCARES oncology certified nurses help patients understand their condition and Jakafi.

A key part of the IncyteCARES program is nurse-facilitated education and information about your condition and Jakafi. Jakafi is a prescription medicine for people with intermediate or high-risk myelofibrosis and for treatment of patients with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it. Our ongoing educational support services provide a partnership approach to care, giving you the tools to more effectively work with your healthcare professional.

 
Jakafi Patient Welcome Kit

Patient Welcome Kit

Once you start taking Jakafi, your specialty pharmacy will send you a Patient Welcome Kit that contains materials and resources to help you understand what to expect from your treatment. This kit includes information about your disease, tools to help you track symptoms you may be having, and detailed information about Jakafi.

 
Jakafi Continuing Education & Support

Ongoing Education and Support

In addition to the welcome kit, you’ll get continuing education about your condition and Jakafi, either through standard mail or email. These materials will offer helpful tips on a range of topics, from how to remember to take your medication to ways to cope with stress.

 
IncyteCARES Certified Oncology Nurses

Access to IncyteCARES Certified Oncology Nurses

Once you enroll in IncyteCARES, you have access to our staff of oncology certified nurses who can help answer questions you may have about myelofibrosis, polycythemia vera, and Jakafi, and help direct you to health and wellness resources.

 

IncyteCARES nurses can also offer personalized assistance to determine if you are eligible for services from foundations and support organizations.

IncyteCARES nurses can be reached at 1-855-4-Jakafi (1-855-452-5234) and are available Monday through Friday, from 8 am to 8 pm, ET.

top-bar
bottom-bar

IncyteCARES education and support FAQs

How do I enroll in the education and support services program?

There are two ways to enroll:
  • Complete and sign the the IncyteCARES enrollment form.
  • Inform an IncyteCARES oncology certified nurse via phone (1-855-452-5234) that you would like to enroll.

Do I have to be taking Jakafi to speak to a nurse?

No. Anyone can call IncyteCARES for general information.


Indications and Usage

Jakafi is a prescription medicine used to treat people with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

Jakafi is also used to treat certain types of myelofibrosis.

Important Safety Information

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi® (ruxolitinib) may cause your platelet, red blood cell, or white blood cell counts to be lowered. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Skin cancers: Some people who take Jakafi have developed certain types of non-melanoma skin cancers. Tell your healthcare provider if you develop any new or changing skin lesions.

Increases in cholesterol: You may have changes in your blood cholesterol levels. Your healthcare provider will do blood tests to check your cholesterol levels during your treatment with Jakafi.

The most common side effects of Jakafi include: low platelet count, low red blood cell counts, bruising, dizziness, headache.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Tell your healthcare provider about any side effect that bothers you or that does not go away.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had tuberculosis (TB) or have been in close contact with someone who has TB, have or had hepatitis B, have or had liver or kidney problems, are on dialysis, had skin cancer, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider. Do not drink grapefruit juice while on Jakafi.

Women should not take Jakafi while pregnant or planning to become pregnant, or if breast-feeding.

Please see Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.